SLC5A2 and Insulin resistance: Two-thirds of the subjects were treated with biguanides, and there were no significant differences in the proportion of baseline treatment with SGLT2 inhibitors and GLP-1 receptor agonists, which might potently affect insulin resistance and β-cell function (Table 1).